IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.42bn
- $13.84bn
- $943.71m
U.S. STOCKS ON THE MOVE-Cytokinetics, Air Lease Corp, Lyft Inc
Ionis Pharma jumps as drug reduces fat levels in late-stage trials
Ionis shares surge after drug to lower blood fat shows promise in trials (updated)
U.S. STOCKS ON THE MOVE-United Therapeutics, Signet Jewelers, Arrowhead
Ionis shares jump after drug lowers blood fat levels in advanced trials
U.S. STOCKS ON THE MOVE-PepsiCo, Ionis Pharma, United Therapeutics
Brief: Ionis Pharmaceuticals Inc - Announces Positive Results From Phase 3 Studies Of Olezarsen - SEC Filing
Ionis Pharma jumps as drug reduces fat levels in trial
U.S. RESEARCH ROUNDUP-Heico, Nordson, Workday
U.S. STOCKS ON THE MOVE-Energy Fuels, Dynavax Technologies, Oklo
US FDA approves Ionis' drug for rare genetic disorder (updated)
Brief: Dawnzera Approved In U.S. As First And Only RNA-Targeted Prophylactic Treatment
Ionis Pharma rises after US FDA approves genetic disorder drug
US FDA approves Ionis' drug for rare genetic disorder (updated)
US FDA approves Ionis' drug for rare genetic disorder
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Drugmaker Ionis's Q2 revenue doubles, beats expectations; hikes guidance
Brief: Tryngolza Recommended For Approval In The EU By CHMP For Familial Chylomicronemia Syndrome
Brief: Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire